British Journal of Cancer · 2002 · 22 citations · 26 references
MedicineOncologyPharmacologyChemotherapyPalliative CarePalliative MedicineGenitourinary Cancer PharmacotherapyMetastatic Disease TreatmentPalliative Care For CancerPalliative ChemotherapyProstate CancerTherapy Response AssessmentAdvanced Prostate Cancer TherapyBody Surface Area - Based DosingChemotherapy For Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Disease PalliationMetastatic Hormone-sensitive Prostate Cancer TherapyPalliative TherapySurvival Rates
The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m(2) of body surface area. The primary end-point was palliative response, defined as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months (range 1-11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles. The 12- and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1-36). The treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3 thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival.
26
N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations
Reporting results of cancer treatment
A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations
The McGill Pain Questionnaire: Major properties and scoring methods
Ronald Melzack · Pain · 1975 · 6.9K citations
Nursing, Psychology, Pain Management +15
I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations
Medicine, Oncology, Pharmacotherapy +17